Overview

Job Title: Director / HR Business Partner

Reports to: CHRO, Menarini Stemline

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 140 countries around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of hematological and solid tumors. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. ELZONRIS® (tagraxofusp) is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). To date, Elzonris is the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123 indications, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and myelofibrosis (MF).

In Europe, Menarini Stemline also commercializes Nexpovio®, a first-in-class oral exportin 1 (XPO1) inhibitor for multiple myeloma in the UK, Switzerland, European Economic Area, CIS countries, Latin America and Turkey. Nexpovio is approved for use in combination with dexamethasone for treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy; and in combination with bortezomib and dexamethasone for treatment of adult patients with multiple myeloma who have received at least one prior therapy. Nexpovio’s marketing authorization is valid in the EU Member States as well as Iceland, Liechtenstein, Norway, and Northern Ireland, and it has been commercially available in Germany and Austria since the fourth quarter of 2022.

In January 2023, Stemline Therapeutics, received U.S. FDA approval for ORSERDU™ (elacestrant), the first and only treatment specifically indicated for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. ESR1 mutations cause tumors to become resistant to endocrine therapy, and up to 40% of patients with ER , HER2- mBC have tumors which harbor this mutation. ORSERDU is the first endocrine innovation in more than 20 years, and specifically addresses a major unmet need. Elacestrant is also being investigated in several clinical trials in metastatic breast cancer disease, alone or in combination with other therapies. A Marketing Authorization Application (MAA) is currently under review by the European Medicines Agency (EMA).

Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumor Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.

Since 2021, MSB is offering in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.

In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.

Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.

Opportunity

The Director (HRBP) provides the unique opportunity to work closely with business leaders and employees at all levels to create and implement business solutions using HR functional experience and expertise. This role will leverage the capabilities of internal functional experts to ensure effective implementation of programs in all areas of HR, including business partnership and employee relations at all levels, talent management and enterprise learning, change, and organizational effectiveness. This role will act as an integrated part of the Global HR Leadership team of Menarini Stemline.

Responsibilities

Business Partnership & Employee Relations

• Embed in the business and with leaders and employees to effectively identify and resolve employee relations issues
• Be a trusted advisor who can counsel leaders, managers, and employees consistent with Menarini Stemline policies/practices

Talent Management & Enterprise Learning

• Identify and plan for future talent needs, while developing the Stemline talent pipeline. Strengthen succession planning and talent readiness
• Develop and implement meaningful and sustainable learning and career development opportunities for Stemline employees
• Create and implement practical retention and engagement opportunities

Change & Organisational effectiveness:

• Develop a strong knowledge of the Stemline business and work with leadership to create and implement practical plans
• Work with leaders and employees in elevating the performance of individuals, teams and, ultimately, Stemline
• Develop and implement plans to ensure the proper organization design, structure, and operating mechanisms.

Other:

• Conduct benchmarking and best practices research as it applies to Oncology / Stemline
• Manage/participate on key projects and initiatives as required.

Qualifications

• 10 years of progressive HR experience in the pharmaceutical industry. Start-up, Biotech and/or Oncology preferred
• Bachelor’s degree required
• SHRM, PHR, or similar certification a plus
• Working knowledge of SuccessFactors, Workday, or other HRIS
• Business partner and employee relations experience supporting multiple functional teams, including R&D, Commercial and Corporate Functions
• Adaptable and pragmatic approach to improve the business through a workforce strategy
• Experience in a high-growth, fast-paced Biotech environment (i.e. scaling for product launch and post-product launch)
• Strong employee relations background
• Talent Management experience, including succession planning and performance management
• Change management experience
• Experience working in a global organization preferred
• Ability to provide first-in-class service to our internal and external stakeholders
• Strong analytical, project management, and problem-solving skills
• Willingness to ‘roll up sleeves’ while still thinking strategically

Candidates should be within commuting distance to Menarini Stemline's NYC offices. Expected business travel and/or onsite requirements in NYC offices will average ~25%.

Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions.

Menarini Stemline is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.